Khademhosseini’s team created a series of integrated microfluidic chips connecting liver organoids and cancer cells. They pumped an anticancer drug through the system, tracking whether it killed the tumor cells and whether the liver cells could survive the toxic onslaught. In this way, they could optimize a drug dosage that maxed cancer-killing power, while keeping the liver out of harm’s way.
